US Patent

US8748573 — Formulations comprising linaclotide

Method of Use · Assigned to Ironwood Pharmaceuticals Inc · Expires 2031-10-30 · 5y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects stable compositions of linaclotide and methods for preparing and using them.

USPTO Abstract

The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions.

Drugs covered by this patent

Linzess (LINACLOTIDE) · AbbVie

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1516`	—	Linzess
`U-1515`	—	Linzess

Patent Metadata

Patent number: US8748573
Jurisdiction: US
Classification: Method of Use
Expires: 2031-10-30
Drug substance claim: No
Drug product claim: No
Assignee: Ironwood Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.